 |
| Advancing Apollo’s human proteins patent position in four key areas: inflammation, cancer, metabolism and regeneration/stem cells |
Apollo's hcx protein development |
Apollo is strengthening its position in human cell expressed (hcx™) proteins by taking 35 of its key human proteins to national phase patenting applications around the world.
"Our IP protection strategy underpins the strength of our competitive advantage in human proteins and delivery platforms," stated Dr Gavin Dixon, Apollo's Director of Intellectual Property.
Apollo is filing national phase patent applications in developed countries/regions such as the US, the European Union, Australia, Canada, Japan and Singapore as well as developing countries such as China and India.
"The US still represents the largest market for therapeutics. At the same time though, countries such as China and India have significant populations that want cutting-edge therapeutics. Further, both countries have made rapid advances in the field of pharmaceutical manufacture over the last 10 years," commented Dr Dixon.
Apollo is also focusing its protein development in the key areas of regeneration (stem cells), inflammation, cancer and metabolism, now that it has put in place a broad platform of more than 100 products.
"These are areas where comparative data shows that hcx™ proteins out-perform those from non-human cells. For example, interferons, which are widely used for treatment of HIV/AIDS and cancer, are mostly produced commercially from E.coli. This means they don’t have the sugar structures that can make up as much as 35% of the molecular weight of the equivalent hcx™ protein. The lack of sugars on these E. coli produced proteins leads to lower antiviral, antiproliferative and immunomodulatory activity," said Dr Dixon.
The patentability of Apollo's hcx™ proteins lies in the combination of their well-characterised "human-like" sugar structures and comparative functional data.
Apollo’s leading position and capability in producing commercially relevant human–derived protein was recently validated by a contract manufacturing agreement with Millipore Corporation, US, to produce a crucial protein for human stem cell research, Leukaemia Inhibitory Factor (LIF), for worldwide markets.
Examples of application areas for Apollo hcx™ protein products
|
Regeneration /Stem Cells
beta-NGF
EPO
EPO R - Fc
FGF basic / FGF-2
FGF R1 alpha (IIIc) - Fc
FGF R4 - Fc
Flt-3 Ligand
G-CSF
GM-CSF
GM-CSF R alpha - Fc
IL-12
IL-2
IL-3
IL-4
IL-4 R alpha - Fc
IL-6
Noggin
NT-3
Oncostatin M
SCF
TGF-beta 1
Thrombopoietin
TNF-alpha
VEGF-121
VEGF-165 |
Cancer
Amphiregulin
CCL-2/MCP-1
CCL-3/MIP-1 alpha
CCL-4/MIP-1 beta
Cripto-1 - Fc
Flt-3 Ligand
Growth Hormone
Growth Hormone R - Fc
IGFBP-3
IL-1ra
IL-6
IL-8
Noggin
Oncostatin M
SCF
TGF-beta 1
TNF-alpha
VEGF-121
VEGF-165
VEGF-C
Metabolism
Adiponectin
Growth Hormone
Growth Hormone - Fc
IGFBP-3
|
Inflammation
Activin RIA - Fc
Adiponectin
Amphiregulin
beta-NGF
CCL-2/MCP-1
CCL-3/MIP-1 alpha
CCL-4/MIP-1 beta
CD40 - Fc
EGF R - Fc
G-CSF
G-CSF R - Fc
GM-CSF
GM-CSF R alpha - Fc
IFN-gamma
IFN-gamma R1 - Fc
IL-1ra
IL-1 RI - Fc
IL-3
IL-3 R alpha - Fc
IL-4
IL-4 R alpha - Fc
IL-5
IL-5 R alpha - Fc
IL-6
IL-8 |
Inflammation (cont'd)
IL-10
IL-10 R alpha - Fc
IL-12
Leptin
L-Selectin - Fc
NGF R - Fc
Oncostatin M
SCF
SCF R - Fc / c-kit - Fc
SCFsR / c-kit
TGF-beta 1
TGF-beta RII - Fc
TNF RI - Fc
TNF RII - Fc
TNF-alpha
TNF-beta / Lymphotoxin-a
TRAIL R1 - Fc
TRAIL R2 - Fc
TrkA - Fc
VEGF
VEGF-C |
|
|
| click to subscribe |
|
 |
| www.apollolifesciences.com |
